TL;DR: The Centers for Medicare & Medicaid Services modified NCD 95 governing injection sclerotherapy for esophageal variceal bleeding, effective March 7, 2026. The policy confirms Medicare coverage under the Physicians' Services benefit category. No specific CPT codes are listed in the policy document itself — and that gap is the first thing your billing team needs to address.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Medicare) |
| Policy | Injection Sclerotherapy for Esophageal Variceal Bleeding |
| Policy Code | NCD 95 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Gastroenterology, General Surgery, Interventional Endoscopy |
| Key Action | Confirm your internal charge capture maps sclerotherapy claims correctly under the Physicians' Services benefit category before billing after March 7, 2026 |
CMS Injection Sclerotherapy Coverage Criteria and Medical Necessity Requirements 2026
The CMS injection sclerotherapy coverage policy under NCD 95 is straightforward on the surface: this procedure is covered under Medicare. Full stop.
Injection sclerotherapy involves inserting a flexible fiberoptic endoscope into the esophagus. The provider then injects a sclerosing agent directly into esophageal varices to stop or control bleeding. CMS classifies this as a Physicians' Services benefit — meaning it runs through Part B, not a specialized DME or facility-only benefit.
The plain-language coverage determination is good news for gastroenterology and surgical billing teams. There's no list of exclusions, no stepwise coverage criteria, and no stated prior authorization requirement in NCD 95 itself. If you're billing Medicare for esophageal variceal sclerotherapy, the Centers for Medicare & Medicaid Services considers this a covered service.
That said, "covered" does not mean "automatically paid." Medical necessity still has to be established at the claim level. Your documentation needs to support the clinical picture — active or recent variceal bleeding, endoscopic findings, and the treating physician's judgment that sclerotherapy was the appropriate intervention. A coverage policy that says yes doesn't protect you from a claim denial if the documentation doesn't hold up.
One thing NCD 95 does not address: prior authorization. There's no prior auth requirement stated in this national coverage determination. But your local Medicare Administrative Contractor may have a Local Coverage Determination that adds criteria on top of NCD 95. Check with your MAC before assuming NCD 95 is the only policy that applies to your claims.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Injection sclerotherapy for esophageal variceal bleeding (control of active or recurrent bleeding via fiberoptic endoscopy with sclerosing agent injection) | Covered | Not specified in NCD 95 — see billing guidelines below | Classified under Physicians' Services benefit; medical necessity documentation required at the claim level |
CMS Injection Sclerotherapy Billing Guidelines and Action Items 2026
The policy itself is short. The billing work it creates is not.
Here's what your team should do before and after the March 7, 2026 effective date:
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for esophageal sclerotherapy claims now. NCD 95 does not list specific CPT codes. That means your billing team is responsible for mapping the correct codes from your EHR or charge description master to this covered service. Pull your last 12 months of sclerotherapy claims and confirm you're using codes that accurately describe the procedure as documented. |
| 2 | Check your MAC's LCD. NCD 95 is a national policy, but Medicare Administrative Contractors can issue Local Coverage Determinations that add or restrict criteria. Contact your MAC or search the CMS LCD database to see whether your jurisdiction has an LCD that governs esophageal sclerotherapy billing. If one exists, it takes precedence over — or layers on top of — NCD 95. |
| 3 | Don't assume "covered" means no prior authorization at the MAC level. NCD 95 doesn't require prior auth. Your MAC might. Verify this before the effective date of March 7, 2026 to avoid claim denials tied to missing authorizations. |
| 4 | Tighten your medical necessity documentation. The policy requires that sclerotherapy be billed under Physicians' Services. That means your notes need to establish physician involvement and medical decision-making clearly. The endoscopic findings, the bleeding indication, and the rationale for sclerotherapy over other interventions should all be explicit in the procedure note. |
| 5 | Review your reimbursement rates for this service. NCD 95 doesn't set the fee schedule — that's separate. But a policy modification is a good trigger to verify that your contracted Medicare rates for sclerotherapy are current and that your billing system reflects the correct allowable amounts. Check the Medicare Physician Fee Schedule for your locality. |
| 6 | If your practice bills globally or splits technical/professional components, confirm the billing split is correct. Sclerotherapy in an outpatient or ASC setting may split between facility and professional claims. Make sure both sides of the claim reflect the Physicians' Services benefit category correctly. |
If you're unsure how your specific claim mix interacts with this policy update, talk to your compliance officer before March 7, 2026.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Injection Sclerotherapy Under NCD 95
A Note on Code Availability
NCD 95 as modified does not include a specific list of CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older NCDs that predate CMS's current code-inclusive policy format — but it does create real work for your billing team.
Do not fabricate codes from context. Do not assume that because a procedure is clinically described, a specific code is implied or covered. Use the procedure documentation and your coding resources (AMA CPT manual, your MAC's LCD, or your certified coder) to assign the correct code for each claim.
The absence of codes in this NCD means the burden of code accuracy falls entirely on your practice. A claim denial tied to an incorrect procedure code won't be resolved by pointing to NCD 95 — because NCD 95 doesn't tell you which code to use.
What to Do Instead of Relying on NCD 95 for Codes
Work with your certified coder or coding consultant to identify the correct CPT code for the specific sclerotherapy service performed. The code should reflect the endoscopic approach, the site (esophageal), and whether any concurrent procedures were performed during the same session.
Check whether your MAC has issued an LCD that includes a covered code list for esophageal sclerotherapy. If so, that list governs your billing — and you should build it into your charge capture and claim scrubbing rules.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.